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Background
The Endoscopic Sleeve Gastroplasty (ESG) is new to
Australia.
It’s minimally invasive procedure is designed to mimic
the Laparoscopic Sleeve Gastropalsty (LSG).
The ENvISaGE Study will observe procedural safety,
change in body composition, comorbidities, and quality
of life in adults undergoing the ESG and LSG.
Objectives and methods
To compare pre-op characteristics of ESG and matched
LSG patients to guide interpretation of post-op
outcomes.
Participants were matched for BMI and gender.
Body composition by DXA, quality of life by Impact of
Weight on Quality of Life Tool-Lite, GI symptoms by
Gastrointestinal Symptom Rating Scale. Bloods, medical
status, adverse events by medical record.
ESG
n=18 recruited
LSG
n=18 recruited
Matched for:
- BMI: mean 35.7 (4.7) kg/m2
- Sex: 83% female
- Age: mean 41.0 (9.7) years
LSG had higher prevalence of anxiety 
and/or depression (56% vs 22%, p<0.05)
ESG had higher systolic blood 
pressure (129 vs 120 mmHG, 
p<0.05)
LSG had higher HbA1c (34 vs 30 
mol/mmol, p<0.01)
LSG had lower high-density 
lipoprotein (1.3 vs 1.6 mmol/L, 
p<0.05)
LSG had worse weight-related self-esteem (11% vs 
29%, p<0.05)
No difference in:
- Pre-op adverse events (0%)
- GORD (35%), Sleep apnoea (31%), Arthritis (61%), 
Backpain (64%), PCOS (8%) 
- T2DM (0%), Fasting blood glucose (5.0mmol/L)
- HTN (30%), diastolic blood pressure (82 mmHg), 
- Dyslipidaemia (9%), T. Chol (5.3mmol/L), LDL 
(3.3mmol/L), HDL (1.4mmol/L), TG (1.5mmol/L)
- NAFLD (5%), ALT (33.3U/L), AST (25.4U/L)
- Gastrointestinal symptoms including reflux, 
constipation, diarrhoea, indigestion, GI pain (35/105 
points)
- Weight-related physical function, sexual life, public 
distress, work, or total quality of life (51%)
- Android to gynoid fat mass ratio (0.57), fat mass 
(47.3%), lean mass (49%)
